Cilag AG - search results

j-c health care ltd - daratumumab - concentrate for solution for infusion - daratumumab 20 mg / 1 ml - daratumumab - darzalex is indicated:• in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.• in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous st em cell transplant.• in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.• as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy

Singapore - English - HSA (Health Sciences Authority)

stelara concentrate for solution for infusion 130mg26ml

johnson & johnson international (singapore) pte ltd - ustekinumab - infusion, solution concentrate - ustekinumab 130mg/vial

Singapore - English - HSA (Health Sciences Authority)

tremfya solution for injection in pre-filled pen 100mgml

johnson & johnson international (singapore) pte ltd - guselkumab - injection, solution - guselkumab 100mg/ml